688192 Dizal
- 39.64
- -2.07-4.96%
Dizal News
Dizhe Pharmaceutical (688192): A globally based differentiated innovative pharmaceutical company
Dizhe Pharmaceutical (688192): The first year of commercialization has begun
Digel Pharmaceuticals (688192): Fast dosage of suvortinib is optimistic about innovative catalysis
Dizhe Pharmaceutical (688192): Revenue is in line with expectations, core products are progressing in an orderly manner worldwide
Dizhe Pharmaceutical (688192): Optimistic about global innovation from a high starting point
Digel Pharmaceuticals (688192): Outstanding commercialization performance of shuvertinib, excellent first-line treatment data
Digel Pharmaceutical-U (688192): Strong sales after Schwogel's launch and global clinical progress smoothly
Digger Pharmaceuticals (688192): Shuvortinib sales set sail, global differentiated pipeline continues to advance
Dietzer Pharmaceutical-U (688192): Shuvertinib approved for marketing, multiple registrations, clinical progress is worth looking forward to
Diezer Pharmaceutical-U (688192): Shuvertinib was approved for marketing, and the first batch of prescriptions was implemented and the research pipeline is progressing smoothly
Digger Pharmaceutical-U (688192): Committed to differentiated competition, is about to enter the commercialization stage
Digger Pharmaceuticals (688192): Source Innovation Is Gradually Entering a Harvest Period, Global Commercialization Accelerates Implementation
Digger Pharmaceuticals (688192): Differentiated pipelines continue to advance, and 2023 will gradually enter a cashing period
Digger Pharmaceuticals (688192): Innovative BIOTECH with global competitiveness
Digger Pharmaceutical-U (688192) 2022 semi-annual report review: The dawn is beginning, and many BICFIC potential products are progressing smoothly globally
Digzhe Pharmaceutical (688192): Global innovation sets sail, and progress can be expected in the internationalization of many products
Analysis
Price Target
No Data
